1. Germany Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Bayer AG

Bayer AG

BAYRY
Bayer AGUS flagOther OTC
13.85
USD
-NaN
- -
54.43BMarket Cap
Bayer AG
BAYRY
(Other OTC)

Recent

price

13.85

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
10.61
11.04
12.01
12.14
12.5
13.93
10.49
9.89
9.76
11.09
10.54
11.22
12.91
12.12
11.86
11.6
11.55
Revenue per Share
0.39
0.75
0.73
0.96
1.04
1.24
1.36
2.07
0.45
1.04
-2.67
0.25
1.06
-0.75
-0.65
-0.92
-0.44
Basic EPS, GAAP
1.29
1.04
0.79
0.91
1.04
1.32
1.96
1.63
1.41
1.42
0.63
0.63
1.05
0.6
1.17
0.88
0.53
Free Cash Flow per Basic Share
0.35
0.38
0.41
0.48
0.53
0.57
0.64
0.67
0.64
0.67
0.7
0.51
0.51
0.61
0.03
0.03
0.03
Dividend per Share
22.41
22.86
21.96
24.66
23.93
28.88
36.1
43.79
49.21
48.1
31.07
33.61
39.47
33.52
32.48
26.41
30.11
Book Value per Share
-1.58
-0.29
-0.36
2.31
-12.96
-8.34
0.54
12.35
-31.56
-27.25
-31.88
-33.94
-25.51
-23.14
-20.58
-23.14
-20.13
Tangible Book Value per Share
3,308
3,308
3,308
3,308
3,308
3,308
3,330
3,541
3,763
3,927
3,930
3,930
3,930
3,930
3,930
3,930
3,930
Basic Weighted Avg Shares
35,088
36,528
39,741
40,157
41,339
46,085
34,943
35,015
36,742
43,545
41,400
44,081
50,739
47,637
46,606
45,575
45,375
Sales/Revenue/Turnover
7.78
11.62
13.2
12.68
13.59
14.74
17.22
17.45
-0.5
10.82
-1.72
15.67
14.45
16.87
7.14
13.47
17.98
Operating Margin (%)
3,556
2,769
2,988
2,896
2,920
3,332
3,063
2,660
6,241
5,367
13,259
3,056
6,503
10,020
8,783
2,785
3,751
Depreciation Expense
1,301
2,470
2,403
3,189
3,426
4,110
4,531
7,336
1,695
4,091
-10,495
1,000
4,150
-2,941
-2,552
-3,620
-1,738
Net Income, GAAP
23.88
26.49
22.76
24.27
24.26
23.36
21.31
29.04
26.3
15.53
- -
50.05
10.79
- -
- -
- -
36.09
Effective Tax Rate (%)
3.71
6.76
6.05
7.94
8.29
8.92
12.97
20.95
4.61
9.39
-25.35
2.27
8.18
-6.17
-5.48
-7.94
-3.83
Profit Margin (%)
7,483
6,678
5,906
5,005
6,724
6,841
11,910
16,480
7,820
9,224
-1,093
3,175
2,676
8,099
5,492
326
1,374
Working Capital
9,582
7,686
6,706
5,044
17,797
16,332
15,375
12,158
37,708
36,907
33,198
36,478
33,781
38,170
35,491
31,806
- -
LT Debt
18,896
19,271
18,551
20,804
20,218
25,445
31,897
36,861
46,064
47,433
30,675
33,168
38,926
33,078
32,045
26,063
29,708
Total Equity
6.8
10.35
13.98
13.78
12.44
12.18
9.81
8.53
-0.2
4.57
- -
4.67
8.47
- -
- -
- -
- -
Return on Invested Capital (%)
4.24
10.81
10.78
13.96
12.22
11.75
10.46
14.36
4.14
6.51
- -
2.28
7.57
- -
- -
- -
11.19
Return on Capital (%)
6.9
12.98
12.76
16.28
16.78
18.53
16.6
21.85
4.1
8.78
-26.99
3.15
11.56
-8.2
-7.87
-12.51
-5.8
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
4,647
- -
- -
LT Borrowings
30,779
- -
- -
LT Finance Leases
1,027
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
982
982
982
Market Capitalization
9,050
9,762
11,781

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
32,911
35,301
33,644
Cash, Cash Equivalents & STI
7,856
6,660
5,082
Accounts Receivable, Net
9,077
12,907
12,880
Inventories
12,335
12,014
11,971
Total Current Liabilities
32,585
33,460
32,270
Payables & Accruals
- -
- -
- -
ST Debt
4,647
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.22%
-2.26%
-18.67%
Free Cash Flow
7.19%
18.61%
-24.99%
Net Income, GAAP
-15.67%
12.64%
41.85%
Sales/Revenue/Turnover
0.57%
2.22%
-2.21%
Total Cash Common Dividend
-6.48%
-21.22%
-3.05%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
13,765
11,144
9,968
11,729
46,606
2025
13,738
10,739
9,660
11,438
45,575
2026
13,405
10,872
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.51
-0.01
-1.06
- -
-0.65
2025
0.33
-0.05
-0.25
- -
-0.92
2026
0.7
0.06
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.03
- -
- -
0.03
2025
- -
0.03
- -
- -
0.03
2026
- -
0.03
- -
- -
- -
Similar Companies
Astellas Pharma Inc. (4503.T)
Merck & Co., Inc. (MRK)
Novartis AG (NVSEF)
Marksans Pharma Limited (MARKSANS.BO)
GuangYuYuan Chinese Herbal Medicine Co., Ltd. (600771.SS)
Pfizer Inc. (PFE)
Business
Bayer AG is a global life science company headquartered in Leverkusen, Germany, primarily engaged in the healthcare and agriculture sectors. The company operates through three main segments: Pharmaceuticals, Consumer Health, and Crop Science. Its Pharmaceuticals segment develops, manufactures, and markets prescription medicines focusing on cardiology, oncology, hematology, ophthalmology, women's health, and specialized therapies including cell and gene therapies. The Consumer Health division offers over-the-counter products spanning nutritional supplements, allergy relief, cough and cold remedies, dermatology products, pain management, cardiovascular risk prevention, and digestive health. Bayer’s Crop Science unit provides products and services in crop protection, seeds and traits, digital farming, fruits and vegetables, and environmental science solutions aimed at sustainable agriculture. Bayer maintains a global footprint with operations across North America, Europe, Asia-Pacific, Latin America, Africa, and the Middle East. Founded in 1863, Bayer continues to be a leader in pharmaceutical and agricultural innovation. In recent major developments during 2024 and 2025, Bayer has continued its corporate restructuring under the Dynamic Shared Ownership operating model introduced in early 2024, aiming to increase agility and operational efficiency. This has involved workforce reductions of approximately 12,000 jobs worldwide, focusing on management and administrative layers, with expected annual cost savings of up to 2 billion euros by 2026. Bayer has advanced a differentiated pharmaceutical pipeline targeting oncology, cardiovascular diseases, neurology, rare diseases, and immunology, with anticipated product launches including treatments for heart failure and hormone-free solutions for menopausal symptoms by the end of 2025. It also pursues growth in cell and gene therapy and targeted radiopharmaceuticals. On the Crop Science front, Bayer is rolling out innovations such as the Preceon Smart Corn System and new herbicides while focusing on digital farming and environmental sustainability. Despite pressure from investors to divest or break up its business units, Bayer has postponed any structural separation, instead emphasizing portfolio management and strategic alliances. The company also navigates significant legal provisions related to litigation over its Roundup weedkiller product. Overall, Bayer maintains a strong commitment to research and development to support its leadership in life sciences globally.

Company News

APIChatGPT

  • zacks.com

    3 Large-Cap Stocks to Watch as Pharma Recovery Takes Hold

  • seekingalpha.com

    Bayer Aktiengesellschaft (BAYRY) Q2 2026 Earnings Call Transcript

  • seekingalpha.com

    Bayer: De-Risking Is Real, But The Pharma Cliff Keeps Me On Hold

  • zacks.com

    BAYRY Beats on Q2 Earnings, Crop Science Business Boosts Growth

  • marketbeat.com

    Bayer Aktiengesellschaft Q2 Earnings Call Highlights

  • wsj.com

    Bayer Swings to Net Profit on Smaller Litigation Charges

  • defenseworld.net

    Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Update

  • businesswire.com

    New Economist Enterprise Research Highlights Why Integrating Self-Care Into Health Systems Matters

  • businesswire.com

    Bayer and Henry Ford Health Announce Strategic Research Partnership to Expand Patient Access to Clinical Trials

  • seekingalpha.com

    Bayer: Debt Remains A Problem, Value Remains Compelling

  • wsj.com

    Apollo to Buy $3.4 Billion Stake in Bayer Contraceptives Business

  • reuters.com

    Bayer gets €3 billion in Apollo deal for contraceptives unit

  • reuters.com

    Bayer seeks US duties on Chinese-made glyphosate, angering farmers

  • fool.com

    Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

  • zacks.com

    BAYRY Stock Surges 17% After Supreme Court Roundup Ruling

  • wsj.com

    Bayer Gets New Life After Supreme Court's Roundup Ruling

  • zacks.com

    Bayer (BAYRY) Moves 17.0% Higher: Will This Strength Last?

  • benzinga.com

    What's Going On With The Surge In Bayer Stock Today?

  • marketwatch.com

    Bayer's stock jumps after Supreme Court sides with Roundup weedkiller manufacturer

  • cnbc.com

    Bayer wins Supreme Court case making it harder to sue over glyphosate in Monsanto's Roundup